

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

May 2018

---

Commission File Number: 001-38067

---

**Verona Pharma plc**  
(Exact Name of Registrant as Specified in Its Charter)

---

3 More London Riverside  
London SE1 2RE UK  
+44 203 283 4200  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

## INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 8, 2018, Verona Pharma plc (the “Company”) issued a press release reporting the purchase of shares by the Chief Executive Officer, Dr. Jan-Anders Karlsson.

The PDMR Press Release is furnished herewith as Exhibits 1 to this Report on Form 6-K.

### EXHIBIT INDEX

Exhibit No.	Description
1	PDMR Dealing

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### VERONA PHARMA PLC

Date: May 4, 2018

By: /s/ Claire Poll

Name: Claire Poll

Title: Legal Counsel



## PDMR Dealing

March 8, 2018, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 7, 2018, Dr. Jan-Anders Karlsson, Chief Executive Officer of the Company, purchased 3,250 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 148.64 pence per Ordinary Share. Following the acquisition, Dr. Karlsson will have an interest in the Company of 92,400 Ordinary Shares, representing 0.09% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name	Jan-Anders Karlsson
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification

<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 5 pence each GB00BYW2KH80
b)	Nature of the transaction	Jan-Anders Karlsson purchased 3,250 Ordinary Shares
c)	Price(s) and volume(s)	
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	7 March 2018
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc  
Jan-Anders Karlsson, Chief Executive Officer

Tel: +44 (0)20 3283 4200  
[info@veronapharma.com](mailto:info@veronapharma.com)

Stifel Nicolaus Europe Limited (Nominated Adviser  
and UK Broker)

Tel: +44 (0) 20 7710 7600  
[SNELVeronaPharma@stifel.com](mailto:SNELVeronaPharma@stifel.com)

Stewart Wallace / Jonathan Senior / Ben Maddison